medigraphic.com
ISSN 1561-297X (Print)

2022, Number 2

<< Back Next >>

Rev Cubana Estomatol 2022; 59 (2)

Mandibular osteonecrosis: clinical and imaging findings in a patient treated with denosumab

Martínez MA, Ortiz PL, Madrid BT, Rojas GAN, Valenzuela SJ

Language: Spanish
References: 31
Page:
PDF size: 765.11 Kb.


ABSTRACT

Introduction: The administration of bisphosphonates and antiangiogenic drugs in cancer patients is a usual therapeutic scheme in oncology. There are reports of osteonecrosis of the jaws in patients undergoing this treatment scheme, after performing an invasive dental procedure.
Objective: Show the dentist from the clinical and imaging characteristics of the pathology on the drugs for the treatment of cancer sensitivity to generate osteonecrosis of the jaws.
Case presentation: An 89-year-old male patient with prostate cancer treated with denosumab developed osteonecrosis of the lower jaw after tooth extraction. It is vitally important that the dentist identifies medications, risk factors and measures to minimize the risk of osteonecrosis of the jaws in sensitivy patients.


REFERENCES

  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1

  2. Svejda B, Muschitz C, Gruber R, Brandtner C, Svejda C, Gasser RW, et al2. . [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Wien Med Wochenschr. 2016;166(1-2):68-74. DOI:10.1007/s10354-016-0437-2

  3. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al3. . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-91. DOI:10.1359/jbmr.0707onj

  4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al4. . American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg; 2014 [Acceso: 30/07/2020];72(10):1938-56. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0278239114004637 4.

  5. Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo; 2017 [Acceso: 30/07/2020];69(1):9. Disponible en: Disponible en: http://www.reumatismo.org/index.php/reuma/article/view/983 5.

  6. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al6. . Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom; 2017 [Acceso: 30/07/2020];20(1):8-24. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1094695016301962 6.

  7. for the MASCC Bone Study Group, Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, et al7. . Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer; 2019 [Acceso: 30/07/2020];27(2):383-94. Disponible en: Disponible en: http://link.springer.com/10.1007/s00520-018-4501-x 7.

  8. Koth VS, Figueiredo MA, Salum FG, Cherubini K. Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non8. condition of bone exposure to a non-exposed BRONJ entity. Dentomaxillofac Radiol; 2016 [Acceso: 30/07/2020];45(7):20160049. Disponible en: http://www.birpublications.org/doi/10.1259/dmfr.20160049

  9. Lorenzo-Pouso AI, Pérez-Sayáns M, Chamorro-Petronacci C, Gándara-Vila P, López-Jornet P, Carballo J, et al. Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Oral Pathol Med. 2020;49(3):190-200.

  10. Rodriguez-Lozano F, Oñate-Sanchez R. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med Oral; 2016 [Acceso: 30/07/2020];0-0. Disponible en: Disponible en: http://www.medicinaoral.com/medoralfree01/aop/20980.pdf 10.

  11. Sartori P, Rajcovich G, Taborda N, Daza MC, Nally C. Osteonecrosis del maxilar inferior por bifosfonatos. Presentación de caso. Rev argent radiol. 2014;66.

  12. Moreno-Sánchez M, Monje Gil F, González-García R, Manzano Solo de Zaldívar D. Bifosfonatos e implantes dentales, ¿son incompatibles? Revisión de la literatura. Rev Esp Cir Oral Maxilofac; 2016 [Acceso: 30/07/202038(3):128-35. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1130055814001294 12.

  13. Diaz-Reverand SA, Naval-Gíaz L, Muñoz-Guerra MF, Sastre-Pérez J, Rodríguez-Campo FJ, Gil-Diez JL, et al13. . Manejo de la osteonecrosis maxilar asociada al uso de medicamentos en virtud de su estadio clínico: análisis de 19 casos. Rev Esp Cir Oral Maxilofac; 2018 [Acceso: 30/07/2020];40(3):104-11. Disponible en: Disponible en: http://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S1130-05582018000300104&lng=es&nrm=iso&tlng=es 13.

  14. Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women: A Randomized Clinical Trial. JAMA Intern Med; 2015 [Acceso: 30/07/2020];175(6):913. Disponible en: Disponible en: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2015.0747 14.

  15. Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, et al15. . Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg; 2018 [Acceso: 30/07/2020];73(2):100-9. Disponible en: Disponible en: https://www.tandfonline.com/doi/full/10.1080/17843286.2017.1348001 15.

  16. Shibahara T. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone. Tohoku J Exp Med; 2019 [Acceso: 30/07/2020];247(2):75-86. Disponible en: Disponible en: https://www.jstage.jst.go.jp/article/tjem/247/2/247_75/_article 16.

  17. Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, et al17. . Five years of anti-resorptive activity after a single dose of zoledronate-Results from a randomized double-blind placebo-controlled trial. Bone; 2012 [Acceso: 30/07/2020];50(6):1389-93. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S875632821200734X 17.

  18. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al18. . Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol; 2012 [Acceso: 30/07/2020];23(5):1341-7. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0923753419346952 18.

  19. Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol; 2012 [Acceso: 30/07/2020];48(9):817-21. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1368837512000978 19.

  20. Eleutherakis-Papaiakovou E, Bamias A. Antiresorptive treatment-associated ONJ. Eur J Cancer Care; 2017 [Acceso: 30/07/2020];26(6):e12787. Disponible en: Disponible en: http://doi.wiley.com/10.1111/ecc.12787 20.

  21. Yamashita J, McCauley LK. Antiresorptives and Osteonecrosis of the Jaw. J. Evid Based Dent Pract; 2012 [Acceso: 30/07/2020];12(3):233-47. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1532338212700465 21.

  22. Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al22. . Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. J Oral Maxillofac Surg; 2010 [Acceso: 30/07/2020];68(2):243-53. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0278239109004418 22.

  23. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al23. . Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat; 2010 [Acceso: 30/07/2020];122(1):181-8. Disponible en: Disponible en: http://link.springer.com/10.1007/s10549-010-0866-3 23.

  24. Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, et al24. . Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int; 2018 [Acceso: 30/07/2020];29(6):1407-17. Disponible en: Disponible en: http://link.springer.com/10.1007/s00198-018-4460-6 24.

  25. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al25. . Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. Am J Med; 2013 [Acceso: 30/07/2020];126(1):13-20. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0002934312005876 25.

  26. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al26. . Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. Arch Intern Med; 2005 [Acceso: 30/07/2020];165(15):1762. Disponible en: Disponible en: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte.165.15.1762 26.

  27. Baba A, Ojiri H, Goto TK, Ikeda K, Yamauchi H, Ogino N, et al27. . Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication). Jpn Dent Sci Rev; 2019 [Acceso: 30/07/2020];55(1):58-64. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1882761618300929 27.

  28. Baba A, Goto TK, Ojiri H, Takagiwa M, Hiraga C, Okamura M, et al28. . CT Imaging Features of Antiresorptive agent-Related Osteonecrosis of the Jaw/ Medication-Related Osteonecrosis of the Jaws. Dentomaxillofac Radiol; 2018 [Acceso: 30/07/2020];20170323. Disponible en: Disponible en: http://www.birpublications.org/doi/10.1259/dmfr.20170323 28.

  29. Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, et al29. . Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg; 2015 [Acceso: 30/07/2020];44(12):1558-64. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0901502715012011 29.

  30. Kagami H, Inoue M, Kobayashi A, Taguchi A, Li X, Yoshizawa M. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws. Oral Dis; 2018 [Acceso: 30/07/2020];24(1-2):52-6. Disponible en: Disponible en: http://doi.wiley.com/10.1111/odi.12783 30.

  31. Eguchi T, Kanai I, Basugi A, Miyata Y, Inoue M, Hamada Y. The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw. Med Oral; 2017 [Acceso: 30/07/2020];0-0. Disponible en: Disponible en: http://www.medicinaoral.com/medoralfree01/aop/22013.pdf 31.




2020     |     www.medigraphic.com